Acceptance of Undertakings in lieu: Anticipated Acquisition by Theramex HQ UK Ltd of the European Rights to Viatris' Femoston and Duphaston products
The CMA has today accepted undertakings in lieu of reference to an in-depth, Phase 2 investigation given by Theramex HQ UK Ltd and Viatris, Inc under section 73 of the Enterprise Act 2002. The anticipated acquisition by Theramex of the European Rights to Viatris' Femoston and Duphaston products will therefore not be referred to an in-depth, Phase 2 investigation and the undertakings which have been signed by Theramex HQ UK Ltd and Viatris, Inc will come into effect from this date.
The text of this decision will be placed on the dedicated case page on the Competition and Markets Authority's website at https://www.gov.uk/cma-cases/theramex-slash-european-rights-to-viatris-femoston-and-duphaston-products as soon as is reasonably practical.
In the event of media enquiries please email press@cma.gov.uk.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
